

**APPENDIX A - SPECIFICATION/CLAIM AMENDMENTS
INCLUDING NOTATIONS TO INDICATE CHANGES MADE**

Serial No.: 09/727,739

Confirmation No. 4181

Docket No.: 255.00040101

In the Claims

For convenience, all pending claims are shown below.

1. An isolated or purified somatostatin polypeptide comprising a polypeptide selected from the group consisting of:
 - (a) a polypeptide comprising SEQ ID NO:15;
 - (b) a subunit of the polypeptide of (a) comprising SEQ ID NO:16 and at least 7 contiguous amino acids from SEQ ID NO:17;
 - (c) an analog of the polypeptide of (a) that has an amino acid sequence at least about 85% identical to SEQ ID NO:15; and
 - (d) an analog of the subunit of (b) having an amino acid sequence at least about 90% identical to the amino acid sequence of the subunit;wherein the somatostatin polypeptide binds to a somatostatin receptor.
2. The somatostatin polypeptide of claim 1, wherein the somatostatin polypeptide comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs:2, 16, 17, 18, and 19.
3. An isolated or purified polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs:15, 17, and 19.
- 4-6 CANCELED
12. A fusion polypeptide comprising an N-terminal somatostatin region comprising at least one first amino acid sequence comprising a somatostatin polypeptide of claim 1 covalently linked to a C-terminal region comprising a second amino acid sequence.

A-2

Amendment - Appendix A
Applicant(s): Sheridan et al.
Serial No.: 09/727,739
Confirmation No.: 4181
Filed: December 1, 2000
Title: SOMATOSTATINS AND METHODS

13. The fusion polypeptide of claim 12 wherein the second amino acid sequence encodes a bioactive moiety.
14. The fusion polypeptide of claim 12 wherein the first amino acid sequence comprises at least one amino acid sequence selected from the group consisting of NOs: 15, 16, 17, 18, and 19.
15. The fusion polypeptide of claim 13 wherein the first amino acid sequence comprises SEQ ID NO:18.